MAPT and Alzheimer disease: From a clinical perspective, research on PSEN1 mutations has shown that individuals carrying variants affecting the transmembrane domain of the presenilin-1 protein experience greater cognitive decline, smaller hippocampal volume, and higher levels of phosphorylated tau, underscoring the relevance of these mutations in AD progression [77].